The present disclosure provides a
dry powder composition of
treprostinil prodrugs and a method of treating
pulmonary hypertension (e.g., pulmonary arterial hypertension), portopulmonary hypertension, or
pulmonary fibrosis in a patient in need thereof. The
dry powder composition includes (a) from about 0.1 wt % to about 3 wt % of a compound of Formula (I):or an
enantiomer,
diastereomer, or a pharmaceutically acceptable salt thereof, (b) from about 0.01 wt % to about 3 wt % of DSPE-PEG2000, (c) from about 10 wt % to about 50 wt % of
leucine, and the balance being (d) a
sugar selected from the group consisting of
trehalose and
mannitol. The entirety of (a), (b), (c), and (d) is 100 wt %, and R1 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl. The method includes administering an effective amount of the
dry powder composition to the lungs of the patient by
inhalation via a
dry powder inhaler. In certain compositions and methods provided herein, R1 is hexadecyl, e.g., linear hexadecyl.